Astellas and Sangamo sign capsid deal for neurological diseases
Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at…
Central Nervous System
-
-
Reprieve for WuXi as Biosecure vote likely pushed to 2025
The Biosecure Act was left out of a key US defence bill that passed in the House last week, in…
-
Muna-GSK alliance to fast-track Alzheimer’s disease treatments
Muna Therapeutics has entered a research alliance with GSK to expedite Alzheimer's disease treatments by discovering and validating new drug…
-
Lundbeck acquires all outstanding shares of Longboard Pharma
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease…
-
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for…
-
CBC acquires UCB’s neurology and allergy business in China
CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature…
-
Acadia signs agreement with Saniona to commercialise SAN711
Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711 for essential tremor, a neurological…
-
Amneal files again for FDA approval of first dihydroergotamine autoinjector
Amneal Pharmaceuticals has submitted another new drug application (NDA) for its dihydroergotamine (DHE) prefilled syringe autoinjector to treat tough-to-treat headaches,…
-
Tris Pharma receives ex-US approvals for ADHD treatments
Tris Pharma has received additional ex-US approvals for its attention deficit hyperactivity disorder (ADHD) treatments, Quillivant XR and QuilliChew ER.…
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
